Cambridge Heart, Inc. (NASDAQOTCBB:CAMH.OB)
The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
WindRules
(< 20)
Submitted: 6/15/2007 5:56:33 PM :
Start Price:
$4.43
CAMH.OB Score:
-88.86
Good product.
Numbers: -.16 this year, projected +.13 next year
PE from -28.26 to +33.69.
marketwatch
Their site: Increase in revenue from first quarter 2006 to first quarter 2007: 83%
Recs
paulmacdo
(< 20)
Submitted: 4/28/2007 11:58:18 AM :
Start Price:
$3.36
CAMH.OB Score:
-90.94
This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.
Recs
aircarp
(< 20)
Submitted: 3/30/2007 10:26:31 PM :
Start Price:
$3.18
CAMH.OB Score:
-95.72
MTWA test now mandatory for Medicare and half of US insured prior to implant of an ICD.
New Sales and Marketing relationship with St. Jude (STJ). 2000 experienced and connected sales professionals will soon be selling the product.
FDA Approved. Patent Holder with mo Competition.
$120M+ Revenue target with 50-65% Margin = $25+ stock over next 2 years.
Recs
obiwankenobe1250
(93.06)
Submitted: 3/22/2007 3:20:15 PM :
Start Price:
$3.23
CAMH.OB Score:
-95.09
Like the news...
Recs
gitau4ever
(32.33)
Submitted: 3/22/2007 1:17:44 PM :
Start Price:
$3.22
CAMH.OB Score:
+94.95
What goes up.. must come down!
Recs
plaidone
(98.34)
Submitted: 2/1/2007 12:46:46 PM :
Start Price:
$2.58
CAMH.OB Score:
+94.14
TMFBent pick.
Recs
mdinvestor
(< 20)
Submitted: 1/17/2007 4:05:24 PM :
Start Price:
$2.21
CAMH.OB Score:
-94.32
Exclusive technology, best data, impending media blitz regarding sudden death by MDT. Defib. companies now realize that MTWA adoption will increase number of defib. implanted.
Impending paradigm shift in this branch of medicine. Pull back due to stockprice getting ahead of itself. Good entry point here.
Goodluck!
Recs
SteadySaber
(76.58)
Submitted: 12/31/2006 7:19:24 PM :
Start Price:
$2.77
CAMH.OB Score:
+95.68
I spoke with a few doctors and they pointed out that the ultimate users and buyers of this equipment have a disincentive to use it because they make more money installing the defibs and therefore don't want to find out what patients will not benefit from the defibs. Moreover, the cost of the machine is so high that only groups of 30-50 can afford to make the purchase and these groups I'm told only conduct a few tests a week. If hospitals start buying it for the cardios then that may change the limitations to some extent. Bottom line, this stock has a huge cult following and therefore I think is overly hyped as is what typically happens in the market. Once reality sets in, they will not be able to sell nearly as many of these equipment as people think. This is one to watch AFTER some decent sales start happening and not before. All the
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 8 of 8